Proliferative retinopathy and maculopathy are two independent conditions in sickle cell disease: Is there a role of blood rheology?1.


Journal

Clinical hemorheology and microcirculation
ISSN: 1875-8622
Titre abrégé: Clin Hemorheol Microcirc
Pays: Netherlands
ID NLM: 9709206

Informations de publication

Date de publication:
2019
Historique:
pubmed: 6 6 2018
medline: 10 8 2019
entrez: 6 6 2018
Statut: ppublish

Résumé

Our study investigated the prevalence of retinopathy and maculopathy in sickle cell patients and tested the association between these two conditions. In addition, we tested whether hematological and hemorheological parameters, as well as genotype, were involved in the development of these two conditions. Seventy sickle cell adult patients were recruited: 37 with sickle cell anemia (SCA) and 33 with sickle cell hemoglobin C disease (SCC). All patients underwent retinal examination and macular ocular coherence tomography. Blood was sampled for the measurements of hematological and hemorheological parameters. Twenty-six patients had maculopathy and 30 had retinopathy with no significant difference between SCA and SCC patients. No association between the presence of retinopathy and maculopathy was detected. RBC aggregation was higher and RBC deformability lower at 3 Pa in SCA patients. Blood viscosity and hematocrit were higher in SCC than in SCA patients. However, no association was found between biological parameters and the ocular complications studied. Our study showed that retinopathy and maculopathy are common in sickle cell disease. Nevertheless, we found no association with hematological parameters, blood rheology or genotype.

Identifiants

pubmed: 29865045
pii: CH180412
doi: 10.3233/CH-180412
doi:

Types de publication

Journal Article

Langues

eng

Pagination

337-345

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Laurence Beral (L)

Service d'Ophtalmologie, CHU de Pointe-à-Pitre/Abymes, route de Chauvel, Pointe-à-Pitre, Guadeloupe, France.
Université des Antilles, CHU dePointe-à-Pitre, Guadeloupe, Université Sorbonne Paris Cité, Université Paris Diderot, Inserm, INTS, Unité Biologie Intégrée du Globule Rouge UMR_S1134, Paris, France.

Nathalie Lemonne (N)

Unité transversale de la Drépanocytose, CHU de Pointe-à-Pitre/Abymes, route deChauvel, Pointe-à-Pitre, Guadeloupe, France.

Marc Romana (M)

Université des Antilles, CHU dePointe-à-Pitre, Guadeloupe, Université Sorbonne Paris Cité, Université Paris Diderot, Inserm, INTS, Unité Biologie Intégrée du Globule Rouge UMR_S1134, Paris, France.
Laboratoire d'Excellence GR-Ex «TheRed Cell: From Genesis to Death», PRES Sorbonne Paris Cité, Paris, France.

Keyne Charlot (K)

Université des Antilles, CHU dePointe-à-Pitre, Guadeloupe, Université Sorbonne Paris Cité, Université Paris Diderot, Inserm, INTS, Unité Biologie Intégrée du Globule Rouge UMR_S1134, Paris, France.
Laboratoire d'Excellence GR-Ex «TheRed Cell: From Genesis to Death», PRES Sorbonne Paris Cité, Paris, France.
UnitéPhysiologie des Exercices et Activités en Conditions Extrêmes, Institut de Recherche Biomédicale desArmées, Brétigny-sur-Orge, France.

Marie Billaud (M)

Unité transversale de la Drépanocytose, CHU de Pointe-à-Pitre/Abymes, route deChauvel, Pointe-à-Pitre, Guadeloupe, France.

Malik Acomat (M)

Service d'Ophtalmologie, CHU de Pointe-à-Pitre/Abymes, route de Chauvel, Pointe-à-Pitre, Guadeloupe, France.

Coralie Zorobabel (C)

Service d'Ophtalmologie, CHU de Pointe-à-Pitre/Abymes, route de Chauvel, Pointe-à-Pitre, Guadeloupe, France.

Elie Nader (E)

Laboratoire d'Excellence GR-Ex «TheRed Cell: From Genesis to Death», PRES Sorbonne Paris Cité, Paris, France.
Laboratoire Interuniversitaire de Biologie de laMotricité (LIBM), EA7424, Equipe Biologie Vasculaire et du Globule Rouge, Université Claude BernardLyon 1, COMUE Lyon, Villeurbanne, France.

Maryse Etienne-Julan (M)

Unité transversale de la Drépanocytose, CHU de Pointe-à-Pitre/Abymes, route deChauvel, Pointe-à-Pitre, Guadeloupe, France.

Thierry David (T)

Service d'Ophtalmologie, CHU de Pointe-à-Pitre/Abymes, route de Chauvel, Pointe-à-Pitre, Guadeloupe, France.

Philippe Connes (P)

Université des Antilles, CHU dePointe-à-Pitre, Guadeloupe, Université Sorbonne Paris Cité, Université Paris Diderot, Inserm, INTS, Unité Biologie Intégrée du Globule Rouge UMR_S1134, Paris, France.
Laboratoire d'Excellence GR-Ex «TheRed Cell: From Genesis to Death», PRES Sorbonne Paris Cité, Paris, France.
Laboratoire Interuniversitaire de Biologie de laMotricité (LIBM), EA7424, Equipe Biologie Vasculaire et du Globule Rouge, Université Claude BernardLyon 1, COMUE Lyon, Villeurbanne, France.
Institut Universitaire de France, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH